Abstract 31P
Background
Incidence rates of breast cancer have been increasing in every country with significant higher proportion of cancer-related mortality particularly in low- and middle-income countries including in Indonesia. Developing novel biomarker is an emerging field in the breast cancer study. Application of a promising minimally-invasive biomarker, circulating microRNA, for additional improvement of diagnosis and therapeutic monitoring in breast cancer is not fully understood.
Methods
We analysed expression of circulating miR-155 in 102 breast cancer patients at diagnosis and after treatment as well as 15 healthy women. Total RNA was extracted from patient’s plasma and microRNA expression was measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression levels of circulating miR-155 were compared according to the effect of treatment, clinicopathological variables, and progression-free survival.
Results
In comparison to the healthy women, expression of circulating miR-155 levels were significantly higher (medians were 18.49±19 and 1.28±0.18, respectively; p < 0.0001). The expression levels of miR-155 were significantly reduced after patients completed surgery and chemotherapy (medians were 18.49±19 at diagnosis and 1.32±0.22 after treatment, respectively; p < 0.0001). Patients older than 40 years old expressed higher circulating miR-155 than those younger than 40 years-old (medians were 28.92±22 and 4.19±2.49, respectively; p < 0.0001). No significant different miR-155 expression levels at diagnosis were observed across tumor grades, sizes, subtypes, and clinical stages. Although patients with circulating miR-155 upregulation have longer progression-free survivals, the difference was not statistically significant compared to those without upregulation. (median survivals were 55 vs 43 weeks and Mantel-Cox test p = 0.7).
Conclusions
Expression of circulating miR-155 expression was significantly elevated in breast cancer patients and was decreased after treatment. Therefore, circulating miR-155 was potentially applicable as diagnostic and therapeutic monitoring marker in breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universities Gadjah Mada.
Funding
The Ministry of Research and Higher Education - Republic of Indonesia (PTUPT 1818/UNI/DITLIT/LT/2018 and PPUPT 1987/UNI/DITLIT/LT/2018).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract